- Home
- NRSN vs RNXT Comparison
NRSN vs RNXT Comparison
Compare NRSN & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- RNXT
- Stock Information
- Founded
- NRSN 2017
- RNXT 2012
- Country
- NRSN Israel
- RNXT United States
- Employees
- NRSN N/A
- RNXT N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- NRSN Health Care
- RNXT Health Care
- Exchange
- NRSN Nasdaq
- RNXT Nasdaq
- Market Cap
- NRSN 37.9M
- RNXT 44.6M
- IPO Year
- NRSN 2021
- RNXT 2021
- Fundamental
- Price
- NRSN $1.79
- RNXT $1.39
- Analyst Decision
- NRSN Buy
- RNXT Strong Buy
- Analyst Count
- NRSN 2
- RNXT 2
- Target Price
- NRSN $14.00
- RNXT $7.25
- AVG Volume (30 Days)
- NRSN 297.9K
- RNXT 243.0K
- Earning Date
- NRSN 06-23-2025
- RNXT 05-15-2025
- Dividend Yield
- NRSN N/A
- RNXT N/A
- EPS Growth
- NRSN N/A
- RNXT N/A
- EPS
- NRSN N/A
- RNXT N/A
- Revenue
- NRSN N/A
- RNXT $240,000.00
- Revenue This Year
- NRSN N/A
- RNXT $3,293.02
- Revenue Next Year
- NRSN N/A
- RNXT $312.06
- P/E Ratio
- NRSN N/A
- RNXT N/A
- Revenue Growth
- NRSN N/A
- RNXT N/A
- 52 Week Low
- NRSN $0.51
- RNXT $0.75
- 52 Week High
- NRSN $1.80
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- NRSN 73.77
- RNXT 71.14
- Support Level
- NRSN $1.65
- RNXT $1.34
- Resistance Level
- NRSN $1.77
- RNXT $1.42
- Average True Range (ATR)
- NRSN 0.14
- RNXT 0.08
- MACD
- NRSN 0.02
- RNXT 0.01
- Stochastic Oscillator
- NRSN 100.00
- RNXT 80.00
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.